Black Diamond Therapeutics, Inc. (BDTX)
Biological Products, (No Diagnostic Substances)
Latest Price
$1.69
TTM P/E
--
Normalized P/E
--
Div Yield
--
Book Value
1.82
P/B Ratio
0.93
Valuation metrics
adjust assumptions →EPS: $0.39
Book value / share: $1.96
Formula: √(22.5 × EPS × BVPS)
Graham Number
$4.15
+146% upside
EPS: $0.39
Target P/E: 15×
Formula: EPS × P/E
P/E Fair Value
$5.85
+246% upside
Institutional Ownership
58.7% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 10.56M | $22.0M | 18.43% | +8.23M | 2026-03-31 |
| NEA Management Company, LLC | 4.45M | $9.0M | 7.76% | -- | 2026-03-31 |
| RENAISSANCE TECHNOLOGIES LLC | 1.64M | $3.0M | 2.87% | +694.0K | 2026-03-31 |
| DIMENSIONAL FUND ADVISORS LP | 1.30M | $2.0M | 2.27% | +444.6K | 2026-03-31 |
| BlackRock, Inc. | 1.11M | $2.0M | 1.93% | +218.6K | 2026-03-31 |
| Connor, Clark & Lunn Investment Management Ltd. | 1.06M | $2.0M | 1.85% | +403.7K | 2026-03-31 |
| MACKENZIE FINANCIAL CORP | 844.8K | $1.0M | 1.47% | +492.4K | 2026-03-31 |
| MARSHALL WACE, LLP | 836.3K | $1.0M | 1.46% | -273.8K | 2026-03-31 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 834.6K | $1.0M | 1.46% | -205.9K | 2026-03-31 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 723.5K | $1.0M | 1.26% | +550.2K | 2026-03-31 |